Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.

doi:10.1016/j.ccell.2021.12.006

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.

Cancer cell - 10 Jan 2022

Dong Liangqing, Lu Dayun, Chen Ran, Lin Youpei, Zhu Hongwen, Zhang Zhou, Cai Shangli, Cui Peng, Song Guohe, Rao Dongning, Yi Xinpei, Wu Yingcheng, Song Nixue, Liu Fen, Zou Yunhao, Zhang Shu, Zhang Xiaoming, Wang Xiaoying, Qiu Shuangjian, Zhou Jian, Wang Shisheng, Zhang Xu, Shi Yongyong, Figeys Daniel, Ding Li, Wang Pei, Zhang Bing, Rodriguez Henry, Gao Qiang, Gao Daming, Zhou Hu, Fan Jia

Abstract excerpt

We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA) using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic analyses prioritized genetic aberrations and revealed hallmarks of iCCA pathogenesis. Aflatoxin signature was associated with tumor initiation, proliferation, and immune suppression. Mutation-associated signaling profiles revealed that TP53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bile Ducts, Intrahepatic

Share to Cholangiocarcinoma

Share to Liver

Share to Prognosis

Share to Proteogenomics

Share to Proteomics

Share to Tumor Microenvironment

Source

Open in PubMed

Identifiers

PMID: 34971568
DOI: 10.1016/j.ccell.2021.12.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.PMID 34971568Read ↗

Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics AnalysisSemantic proximity Read ↗

Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Integrative Sequencing and Proteogenomic Approaches to Intratumoral Heterogeneity in Cholangiocarcinoma: Implications for Precision Diagnosis and Therapy.Semantic proximity Read ↗

Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer TypeSemantic proximity Read ↗

Molecular Subtypes and Precision Oncology in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Recent Advances in Pathology of Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.Semantic proximity Read ↗

Proteogenomic characterization reveals antitumor mechanisms of intrahepatic cholangiocarcinomaSemantic proximity Read ↗

Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinomaSemantic proximity Read ↗

Molecular mechanisms and genetic features of cholangiocarcinoma: implications for targeted therapeutic strategiesSemantic proximity Read ↗

Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy.Semantic proximity Read ↗

Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.